Month: October 2022

In, Jinkyung; Hwang, Soonho; Kim, Changhun; Seo, Jae Hong; Kim, Sanghee published an article in 2013, the title of the article was Synthesis of 3,4-Dihydroisoquinolin-1-ones from N-Boc-(β-Arylethyl)carbamates via Isocyanate Intermediates.Safety of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one And the article contains the following content:

Mild reaction conditions for the regioselective synthesis of isoquinolin-1-ones and related fused-ring heterocycles from N-Boc-protected (β-arylethyl)carbamates are described. The reactions involved the use of Tf2O and 2-chloropyridine and isocyanates are likely to be key intermediates. The method was extended to substrates bearing less nucleophilic aryl moieties by using Lewis acid additives, such as BF3·Et2O, to enhance the Friedel-Crafts-type cyclization of the isocyanate intermediates. This method allowed the synthesis of various substituted isoquinolin-1-ones, β-carbolines, thiophene-fused ring systems and tetrahydrobenzoazepin-1-ones in good yields and with high regioselectivities. The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).Safety of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one

The Article related to dihydroisoquinolinone synthesis arylethylcarbamate isocyanate intermediate cyclization, Heterocyclic Compounds (One Hetero Atom): Quinolines and Isoquinolines and other aspects.Safety of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On January 29, 2004, Yamada, Rintaro; Seto, Minoru published a patent.Safety of 4-Bromo-5-nitroisoquinoline The title of the patent was Preparation of 5-substituted isoquinoline derivatives as myosin regulatory light-chain phosphorylation inhibitors. And the patent contained the following:

The title compounds I [wherein R1 = H, halo, OH, NH2, or alkoxy; R2 = H, halo, alkenyl, alkynyl, alkoxy,alkylthio, alkyl-SO, alkylsulfonyl, CN, (un)substituted alkyl, amino, etc.; R3 = (un)substituted OH, SO2NH2, or NH2] or salts thereof are prepared as myosin regulatory light-chain phosphorylation inhibitors. For example, N-(tert-butoxycarbonyl)-1,3-propanediamine was reacted with isoquinoline-5-sulfonyl chloride in CH2Cl2 in the presence of NEt3 to give the sulfonamide. The sulfonamide was reacted with 3-phenyl-1-propanol in THF in the presence of 1,1′-azobis(N,N-dimethylformamide) and Bu3P, followed by hydrolysis to provide II•xHCl. II showed inhibitory activity with IC50 of 0.8 μM against human myosin regulatory light-chain phosphorylation. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).Safety of 4-Bromo-5-nitroisoquinoline

The Article related to isoquinoline myosin regulatory light chain phosphorylation inhibitor preparation human, Heterocyclic Compounds (One Hetero Atom): Quinolines and Isoquinolines and other aspects.Safety of 4-Bromo-5-nitroisoquinoline

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On July 1, 2006, Jesudason, Cynthia D.; Beavers, Lisa S.; Cramer, Jeffrey W.; Dill, Joelle; Finley, Don R.; Lindsley, Craig W.; Stevens, F. Craig; Gadski, Robert A.; Oldham, Samuel W.; Pickard, R. Todd; Siedem, Christopher S.; Sindelar, Dana K.; Singh, Ajay; Watson, Brian M.; Hipskind, Philip A. published an article.COA of Formula: C10H11NO2 The title of the article was Synthesis and SAR of novel histamine H3 receptor antagonists. And the article contained the following:

The synthesis and biol. evaluation of novel tetrahydroisoquinoline, tetrahydroquinoline, and tetrahydroazepine antagonists of the human and rat H3 receptors are described. The substitution around these rings as well as the nature of the substituent on nitrogen is explored. Several compounds with high affinity and selectivity for the human and rat H3 receptors are reported. The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).COA of Formula: C10H11NO2

The Article related to h3 antihistaminic tetrahydroisoquinoline tetrahydroquinoline tetrahydroazepine preparation, Heterocyclic Compounds (One Hetero Atom): Quinolines and Isoquinolines and other aspects.COA of Formula: C10H11NO2

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On January 10, 2013, Frackenpohl, Jens; Zeiss, Hans-Joachim; Heinemann, Ines; Willms, Lothar; Mueller, Thomas; Busch, Marco; Von Koskull-Doering, Pascal; Rosinger, Christopher Hugh; Dittgen, Jan; Hills, Martin Jeffrey published a patent.SDS of cas: 74904-29-3 The title of the patent was Use of substituted isoquinolinones, isoquinolinediones, isoquinolinetriones and dihydroisoquinolinones or in each case salts thereof as active agents against abiotic stress in plants and their preparation. And the patent contained the following:

The invention relates to the use of substituted isoquinolinones, isoquinolinediones, isoquinolinetriones and dihydroisoquinolinones of formula I or in each case salts thereof, for enhancing stress tolerance in plants against abiotic stress, for boosting plant growth and/or for increasing plant yield, and to special methods for producing the aforementioned compounds Compounds of formula I wherein Q is (un)substituted ethylene, (un)substituted ethenylene, (un)substituted oxoethylene, etc.; W is O and S; R1, R2, R3 and R4 are independently H, NO2, amino, OH, halo, etc.; R5 is H, OH, alkyl, cycloalkyl, etc.; and their salts are claimed. Example compound II was prepared by a multistep procedure (procedure given). All the invention compounds were evaluated for their ability to protect against abiotic stress in plants (some data given). The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).SDS of cas: 74904-29-3

The Article related to isoquinolinone isoquinolinedione isoquinolinetrione preparation protection abiotic stress plant, Heterocyclic Compounds (One Hetero Atom): Quinolines and Isoquinolines and other aspects.SDS of cas: 74904-29-3

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

Sall, Daniel J.; Grunewald, Gary L. published an article in 1987, the title of the article was Inhibition of phenylethanolamine N-methyltransferase (PNMT) by aromatic hydroxy-substituted 1,2,3,4-tetrahydroisoquinolines. Further studies on the hydrophilic pocket of the aromatic ring binding region of the active site.Related Products of 74904-29-3 And the article contains the following content:

In a study directed toward characterizing the hydrophilic pocket within the aromatic ring binding region of the active site of phenylethanolamine N-methyltransferase (PNMT), 5-, 6-, 7-, and 8-hydroxy-1,2,3,4-tetrahydroisoquinoline were prepared and evaluated as substrates and inhibitors of PNMT. Thus, 2-MeOC6H4CH2CH2NHCO2Me was cyclized by polyphosphoric acid to give 8-methoxy-3,4-dihydroisoquinolin-1-one, which was reduced followed by demethylation to give 8-hydroxy-1,2,3,4-tetrahydroisoquinoline. In order to discern the necessity of an acidic hydrogen for interaction at this pocket the corresponding Me ethers were also evaluated. The enhanced affinity of 7-hydroxy-1,2,3,4-tetrahydroisoquinoline vs. tetrahydroisoquinoline itself indicates that a hydrophilic pocket exists off of carbon C7 in bound tetrahydroisoquinolines. The Me ethers of 5-, 6-, 7-, and 8-hydroxy-exo-2-aminobenzonorbornene and of 5- and 6-hydroxy-anti-9-aminobenzonorbornene were also evaluated for their activity as substrates and inhibitors for PNMT. The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).Related Products of 74904-29-3

The Article related to isoquinolinol tetrahydro preparation pnmt inhibition, phenylethanolamine methyltransferase inhibition, Heterocyclic Compounds (One Hetero Atom): Quinolines and Isoquinolines and other aspects.Related Products of 74904-29-3

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On November 2, 2000, Mewshaw, Richard Eric; Meagher, Kristin Lynne published a patent.Computed Properties of 74904-29-3 The title of the patent was Preparation of tetrahydroisoquinolinylindole derivatives for the treatment of depression. And the patent contained the following:

The title compounds I [R1-R4 = H, halo, alkoxy, carboxamide; R5 = H, halo, CF3, CN, carbamide, alkoxy; X = (CH2)n, 4-6 membered carbocyclic ring, wherein n is an integer of 2 to 4], useful for the treatment of depression, were prepared E.g., 3-[(1,4-cis)-4-(7-methoxy-3,4-dihydro-1H-isoquinolin-2-yl)cyclohexyl]-1H-indole-5-carbonitrile was prepared by reaction of 7-methoxy-1,2,3,4-tetrahydroisoquinoline (preparation given) with 4-(5-cyano-1H-3-indolyl)cyclohexanone in presence of sodium triacetoxyborohydride and acetic acid in CH2Cl2. I are active towards 5HT1A receptors and generally elevate serotonin levels by inhibiting 5-HT transport. The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).Computed Properties of 74904-29-3

The Article related to isoquinolinylindole preparation depression treatment, indole isoquinolinyl preparation depression treatment, Heterocyclic Compounds (One Hetero Atom): Quinolines and Isoquinolines and other aspects.Computed Properties of 74904-29-3

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On May 14, 2020, Lee, Matthew Randolph; Varano, Anthony Joseph published a patent.Reference of 4-Bromo-5-nitroisoquinoline The title of the patent was Sulfonylisoquinoline derivatives as Rock kinase inhibitors and their preparation. And the patent contained the following:

The invention relates to compounds of formula I as Rho-associated protein kinases (ROCK) inhibitors useful for treatment of cerebral cavernous malformation syndrome and cardiovascular diseases. Compounds of formulas I and II wherein ring X is partially saturated aza-containing heteroaryl; Y is CH or N; m is 0, 1, 2 and 3; each R1 is independently CN, OH, hydroxyalkyl, halo, etc.; R2 is H and halo; R3 is H, halo and C1-3 alkyl; with provisions; and pharmaceutically acceptable salts thereof, are claimed. Example compound III was prepared by sulfonylation of 1-chloroisoquinoline with chlorosulfonic acid; the resulting 1-chloroisoquinoline-5-sulfonyl chloride underwent hydrolysis to give 1-hydroxyisoquinoline-5-sulfonic acid, which underwent chlorination to give the corresponding sulfonyl chloride, which underwent amidation with 4-methylisoindoline to give compound III. Exemplified I were evaluated for selective ROCK kinase inhibitory activity from which III demonstrated IC50 values in the range of >1000 nM and ≤10,000 nM for both ROCK1 and ROCK2 compared to IC50 values of >10,000 for PKACA, AKT1, and PKG, resp. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).Reference of 4-Bromo-5-nitroisoquinoline

The Article related to sulfonylisoquinoline derivative preparation rock kinase inhibitor cavernous malformation syndrome, selective rock1 rock2 inhibitor cardiovascular disease, Heterocyclic Compounds (One Hetero Atom): Quinolines and Isoquinolines and other aspects.Reference of 4-Bromo-5-nitroisoquinoline

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On September 2, 2005, Yamada, Rintaro; Seto, Minoru published a patent.Related Products of 58142-46-4 The title of the patent was Preparation of isoquinoline derivatives as inhibitors of myosins light chain phosphorylation. And the patent contained the following:

The title compounds I [wherein R1 = H, halo, OH, NH2, or alkoxy; R2 = H, halo, alkyl, etc.; R3 = (un)substituted OH, NH2, or SO2NH2] or salts thereof are prepared as inhibitors of myosins light chain phosphorylation for the treatment of glaucoma, chronic obstructive pulmonary disease, asthma, etc. For example, the compound II•xHCl was prepared II•xHCl inhibited human myosins light chain phosphorylation with IC50 of 0.8 μM. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).Related Products of 58142-46-4

The Article related to isoquinoline preparation inhibitor myosin regulatory light chain phosphorylation obstruction, human treatment glaucoma chronic obstructive pulmonary disease asthma, Heterocyclic Compounds (One Hetero Atom): Quinolines and Isoquinolines and other aspects.Related Products of 58142-46-4

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On July 28, 2005, Taveras, Arthur G.; Zheng, Junying; Biju, Purakkattle J.; Yu, Younong; Chao, Jianhua; Fine, Jay; Lundell, Daniel; Priestley, Tony; Reggiani, Angelo; Merritt, J. Robert; Baldwin, John J.; Lai, Gaifa; Wu, Minglang published a patent.Electric Literature of 74904-29-3 The title of the patent was Preparation of isothiazole dioxides as CXC- and CC-chemokine receptor ligands. And the patent contained the following:

Disclosed are novel compounds I [D, E = N, CR50; provided that D and E are not the same (one is N and the other is CR50); R50 = H, CF3, CN, etc.; A = (hetero)aryl, (hetero)arylalkyl; B = (hetero)aryl] and the pharmaceutically acceptable salts and solvates thereof. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenesis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound I. Although the methods of preparation are not claimed, hundreds of example preparations and/or characterization data are included. For example, II was prepared in 68% yield from the isothiazoledioxide III and the amine IV.pTSA (preparation of reactants given). Antagonist activities of some examples of I towards CXCR1, CXCR2 and CCR7 are given. The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).Electric Literature of 74904-29-3

The Article related to isothiazole dioxide preparation chemokine receptor antagonist cxcr1 cxcr2 ccr7 and other aspects.Electric Literature of 74904-29-3

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On January 10, 1990, Comte, Marie Therese; Gueremy, Claude; Malleron, Jean Luc; Mignani, Serge; Peyronel, Jean Francois; Truchon, Alain published a patent.Recommanded Product: 58142-46-4 The title of the patent was Preparation and formulation of (aza)naphthalenesultam derivatives as serotoninergic antagonists. And the patent contained the following:

Title compounds I [R1 = 4-(hetero)aryl-substituted 1,2,3,6-tetrahydro-1-pyridyl, 1-piperazinyl, or piperidino; R2, R3 = H, halo, R4 = H; or R2 = R4 = H, R3 = halo, AcNH; or R2 = R3 = H, R4 = halo, all with X = CH; or R2 = R3 = R4 = H, X = N; Z = (un)substituted alkylene; various provisos] were prepared as serotonergic 5-HT2 receptor antagonists (no data). Thus, N-alkylation of 1,8-naphthosultam by Br(CH2)3Cl using NaH in DMF gave the N-(3-chloropropyl) derivative, which reacted with 1-(4-fluorophenyl)piperazine in PhMe containing Et3N to give (piperazinylpropyl)naphthoisothiazole derivative II. Three formulations and 61 syntheses are given. The IC50 of I for displacement of [3H]-ketanserin from 5-HT receptors are said to be generally <25 nM. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).Recommanded Product: 58142-46-4

The Article related to naphthalenesultam preparation serotoninergic antagonist, naphthoisothiazole preparation 5ht antagonist, Heterocyclic Compounds (More Than One Hetero Atom): Thiazoles, Isothiazoles and other aspects.Recommanded Product: 58142-46-4

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem